Premium
Activation of Peripheral delta 2 opioid receptors by Deltorphin‐B (Delt‐B) increased cardiac tolerance to arrythmogenic impact of ischemia/reperfusion
Author(s) -
Oeltgen Peter R.,
Maslov Leonid N.,
Brown Stephen A.
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.781.3
Subject(s) - nociceptin receptor , damgo , agonist , naltrindole , opioid , dermorphin , antagonist , medicine , opioid receptor , ischemia , opioid antagonist , (+) naloxone , pharmacology , anesthesia , endocrinology , opioid peptide , chemistry , receptor
We investigated the role of peripheral μ, δ 1, δ 2 and opioid receptor ligands (ORL1) in the regulation of cardiac tolerance to the arrhythmogenic impact of ischemia reperfusion in rats. The ligands were given prior to 45 min coronary artery occlusion and 10 min reperfusion. The incidence of ventricular arrythmias was determined. Pretreatment with the Delt‐B (150 nmol/kg) reduced incidence of ischemia and reperfusion induced arrhythmias. The δ 2 OR agonists Deltorphin‐D variant (150 nmol/kg) and Deltorphin‐E (150 nmol/kg) prevented an appearance of arrhythmias only during phase 1b ischemia. The μ OR agonists DAMGO (150 and 1500 nmol/kg) and Dermorphin‐H (150 nmol/kg), the δ 1 OR agonist DPDPE (150 and 1500 nmol/kg) and the ORL1 receptor agonist Nociceptin (220 and 1500 nmol/kg) had no effect on the incidence of arrhythmias. Pretreatment with universal opioid antagonist naloxone methiodide and naltrexone and δ 2 specific OR antagonist naltriben methane sulfonate (NTB) abolished the antiarrhythmic effect of Delt‐B. The selective δ 1 OR antagonist 7‐Benzylidenenaltrexone (BNTX) had no effect. The OR antagonists alone did not exhibit antiarrhythmic properties. δ 2 receptor activation by Deltorphins increases tolerance to arrhythmogenic impact of ischemia/reperfusion in rats. Supported by the Office of Navel Research (PRO), a VA Merit Review Grant (SAB) and the Russian Foundation of Basic Research (LNM).